Merck , known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir , an investigational antiviral agent.
http://ift.tt/1nXjQ7k
http://ift.tt/1nXjQ7k
Stem Cell Research News: News on Stem Cell Research continually updated from thousands of sources around from the B Media Network.
No comments:
Post a Comment